[ad_1]
Santa Ana, California, July 24, 2021 /PRNewswire/-Johnson & Johnson Vision*, a global leader in eye health and part of Johnson & Johnson Medical Devices **, today announced the results of a new comparative clinical study that evaluated TearScience LipiFlow treatment in cataract surgery. The data concluded that, compared with the control group, the use of TearScience LipiFlow before cataract surgery in patients treated with TearScience LipiFlow significantly reduced patient-reported halos (58.6% vs. 79%), and the Meibomian Gland Score (MGD) improved more than Control group (107 vs. 66 percent). The results are shared today in a poster presentation at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) and the American Association of Ophthalmologists (ASOA).
The study is titled “Preoperative treatment of telephoto intraocular lens implantation with preoperative heat pump system for treatment of meibomian gland dysfunction,” is a post-marketing, prospective, randomized, multicenter, bilateral, open-label, crossover, and comparative clinical study, covering five US locations, including 115 subjects. Three months after surgery, in the study group and The ratio of disturbing ocular symptoms (such as seeing halos) between the control group. These findings are consistent with the recent ASCRS clinical guidelines, which recommend proactive diagnosis and management of MGD for preoperative cataract patients.1
“We continue to learn more about the link between ocular surface health and vision results after cataract surgery,” Daniel Chang,Medical PhD.*** “This new data emphasizes the importance of proactive screening and treatment of MGD before cataract surgery. This is a simple addition to the patient’s treatment plan and may bring better visual effects to our patients.”
MGD is a popular, chronic, and progressive disease. The longer it is left untreated, the more serious the condition will be.2,3,4,5 In this study, preoperative TearScience LipiFlow for cataract patients improved meibomian gland function and improved preoperative eye health. In addition to reducing reports of postoperative halos, preoperative treatment also showed a significant improvement in vision (20/20 at 4 meters, 20/20 at 66 cm; 20/30 at 40 cm).
“As clinicians, we have always hoped to optimize the surgical results of cataract patients, including postoperative visits. The data we announced today strengthen the necessity for surgeons to screen and treat MGD before cataract surgery, especially considering the high incidence and The nature of the ocular surface disease in asymptomatic cataract surgery patients,” Rajesh Rajpal, MD, Chief Medical Officer of Johnson & Johnson Vision and Global Head of Clinical and Medical Affairs.
This Learn It can be watched on demand in the education center of the conference center during the conference,…
The full story can be found on Benzinga.com
[ad_2]
Source link
